Pulmonary hypertension: Difference between revisions

No edit summary
(Strip excess bold text)
 
Line 8: Line 8:


===WHO Classification<ref>Ryan, J. et al. (2012) The WHO classification of pulmonary hypertension: A case-based imaging compendium. Pulmonary Circulation, 2(1).</ref>===
===WHO Classification<ref>Ryan, J. et al. (2012) The WHO classification of pulmonary hypertension: A case-based imaging compendium. Pulmonary Circulation, 2(1).</ref>===
*'''Group 1''': Pulmonary ''arterial'' hypertension
*Group 1: Pulmonary ''arterial'' hypertension
**Idiopathic
**Idiopathic
**Associated with:
**Associated with:
Line 16: Line 16:
***Portal hypertension
***Portal hypertension
***[[Congenital heart disease]]
***[[Congenital heart disease]]
*'''Group 2''': PH due to left heart disease
*Group 2: PH due to left heart disease
**Associated with:
**Associated with:
***Coronary artery disease
***Coronary artery disease
Line 22: Line 22:
***[[Valvular disease]]
***[[Valvular disease]]
***Advanced age
***Advanced age
*'''Group 3''': PH due to lung diseases
*Group 3: PH due to lung diseases
**Associated with:
**Associated with:
***[[COPD]]
***[[COPD]]
***[[Interstitial lung disease]]
***[[Interstitial lung disease]]
***Any other lung disease causing [[hypoxemia]]
***Any other lung disease causing [[hypoxemia]]
*'''Group 4''': PH due to chronic [[thromboembolism|thromboembolic disease]]
*Group 4: PH due to chronic [[thromboembolism|thromboembolic disease]]
*'''Group 5''': PH of unclear multifactorial mechanisms
*Group 5: PH of unclear multifactorial mechanisms
**Associated with:
**Associated with:
***[[Sarcoidosis]]
***[[Sarcoidosis]]
Line 65: Line 65:
[[File:PulArtHyperandEmphysemaMark.png|thumb|CT chest with contrast showing prulmonary artery hypertension (red arrow) and evidence of emphysema (blue arrow).]]
[[File:PulArtHyperandEmphysemaMark.png|thumb|CT chest with contrast showing prulmonary artery hypertension (red arrow) and evidence of emphysema (blue arrow).]]
''Some, all or none of the following findings may be present.''
''Some, all or none of the following findings may be present.''
*'''[[BNP]]:''' Elevated<ref name="Wilcox"></ref>
*[[BNP]]: Elevated<ref name="Wilcox"></ref>
*'''[[ECG]] findings''' (similar to acute pulmonary embolism):
*[[ECG]] findings (similar to acute pulmonary embolism):
**Right axis deviation
**Right axis deviation
**Evidence of right heart strain on bedside ultrasound or CT
**Evidence of right heart strain on bedside ultrasound or CT
Line 88: Line 88:
*Tricuspid valve regurgitation
*Tricuspid valve regurgitation
*Estimate systolic pulmonary artery pressure (SPAP) with echo<ref>Critical USG. Echocardiographic assessment of pulmonary artery pressure. 2012. http://www.criticalusg.pl/en/echo/tte/tutorials/echocardiographic-assessment-of-pulmonary-artery-pressures</ref>
*Estimate systolic pulmonary artery pressure (SPAP) with echo<ref>Critical USG. Echocardiographic assessment of pulmonary artery pressure. 2012. http://www.criticalusg.pl/en/echo/tte/tutorials/echocardiographic-assessment-of-pulmonary-artery-pressures</ref>
**SPAP = '''Max TR gradient''' + '''Mean RAP'''
**SPAP = Max TR gradient + Mean RAP
**Cannot use this method with vent-dependent patients, pulmonic stenosis
**Cannot use this method with vent-dependent patients, pulmonic stenosis
**Max TR gradient as measured by tricuspid regurgitation (TR) jet, which >90% of adults have
**Max TR gradient as measured by tricuspid regurgitation (TR) jet, which >90% of adults have
**Use parallel CW Doppler line across TR jet in apical view
**Use parallel CW Doppler line across TR jet in apical view
**Obtain dense TR profile below the line with well-defined envelope and measure peak = '''Max TR gradient'''
**Obtain dense TR profile below the line with well-defined envelope and measure peak = Max TR gradient
**Estimate right atrial pressure (RAP) with IVC diameter from subcostal view
**Estimate right atrial pressure (RAP) with IVC diameter from subcostal view
{|class="wikitable"
{|class="wikitable"
Line 126: Line 126:


===Optimize Circulation===
===Optimize Circulation===
#'''Optimize (usually reduce) RV preload''':
#Optimize (usually reduce) RV preload:
#*Usually euvolemic or hypervolemic, rarely need IV fluids so [[diuretics]] can benefit and treat the RV failure<ref>Ternacle, J et al. Diruetics in Normotensive Patients with Acute Pulmonary Embolism and Right Ventricular Dilation. Circulation Journal. Vol 77(10) 2013. 2612-618.</ref>
#*Usually euvolemic or hypervolemic, rarely need IV fluids so [[diuretics]] can benefit and treat the RV failure<ref>Ternacle, J et al. Diruetics in Normotensive Patients with Acute Pulmonary Embolism and Right Ventricular Dilation. Circulation Journal. Vol 77(10) 2013. 2612-618.</ref>
#**[[Furosemide]] 20-40mg IV  
#**[[Furosemide]] 20-40mg IV  
#**Furosemide drip at 5-20mg/hr
#**Furosemide drip at 5-20mg/hr
#*If suspect [[sepsis]] or [[hypovolemia]], small (250-500cc) NS challenge to assess fluid responsiveness.  If not responsive to IVF challenge, start [[vasopressin]] or [[norepinephrine]](MAP > 65 mmHg).  
#*If suspect [[sepsis]] or [[hypovolemia]], small (250-500cc) NS challenge to assess fluid responsiveness.  If not responsive to IVF challenge, start [[vasopressin]] or [[norepinephrine]](MAP > 65 mmHg).  
#'''Increase cardiac output''':
#Increase cardiac output:
#*Once MAP >65 mmHg, start low dose [[dobutamine]] (5-10mcg/kg/min)
#*Once MAP >65 mmHg, start low dose [[dobutamine]] (5-10mcg/kg/min)
#*Improves inotropic support and theoretically decreases pulmonary vascular resistance
#*Improves inotropic support and theoretically decreases pulmonary vascular resistance
#'''Reduce RV afterload''':
#Reduce RV afterload:
#*Avoid [[hypoxia]], maintain O2 sat >90% (increases pulmonary vasoconstriction)
#*Avoid [[hypoxia]], maintain O2 sat >90% (increases pulmonary vasoconstriction)
#*Avoid [[hypercapnia]] (increases pulmonary vascular resistance)
#*Avoid [[hypercapnia]] (increases pulmonary vascular resistance)
#*Avoid [[acidosis]]
#*Avoid [[acidosis]]
#'''Treat [[arrhythmias]]:'''
#Treat [[arrhythmias]]:
#*[[SVT]] most common although may also become bradycardic (aflutter and afib occur equally)
#*[[SVT]] most common although may also become bradycardic (aflutter and afib occur equally)
#*Treatment of aflutter is often more successful than afib
#*Treatment of aflutter is often more successful than afib
Line 146: Line 146:


===Optimize Oxygenation===
===Optimize Oxygenation===
*'''noninvasive oxygenation:''' attempt nonrebreather mask or high flow nasal cannula to maximize oxygenation. Use NIPPV with caution as positive pressure decreases preload and increases right sided pressures.  
*noninvasive oxygenation: attempt nonrebreather mask or high flow nasal cannula to maximize oxygenation. Use NIPPV with caution as positive pressure decreases preload and increases right sided pressures.  
*'''Intubate as a last resort:''' RSI meds cause hypotension worsening RV ischemia. hypercapnea and hypoxia worsen pulmonary artery vasoconstriction. positive pressure ventilation decreases preload and increases right sided pressures.  
*'''Intubate as a last resort:''' RSI meds cause hypotension worsening RV ischemia. hypercapnea and hypoxia worsen pulmonary artery vasoconstriction. positive pressure ventilation decreases preload and increases right sided pressures.  
*'''Intubated patients''' should be optimized to increased O2 delivery and minimize hypercapnia, maintain low tidal volumes and low PEEP as tolerated
*'''Intubated patients''' should be optimized to increased O2 delivery and minimize hypercapnia, maintain low tidal volumes and low PEEP as tolerated
Line 158: Line 158:
==Chronic Therapies==
==Chronic Therapies==
===Prostacyclins===
===Prostacyclins===
'''Mechanisms of action''': vasodilatation, inhibit platelet aggregation
Mechanisms of action: vasodilatation, inhibit platelet aggregation
*[[Epoprostenol]], Iloprost, Treprostinil, Beraprost
*[[Epoprostenol]], Iloprost, Treprostinil, Beraprost
**Complications include acute decompensation if stopped abruptly, diarrhea, edema, headache
**Complications include acute decompensation if stopped abruptly, diarrhea, edema, headache
===Phosphodiesterase Type 5 (PDE5) Inhibitors===
===Phosphodiesterase Type 5 (PDE5) Inhibitors===
'''Mechanism of Action''': vasodilation, increases RV contractility
Mechanism of Action: vasodilation, increases RV contractility
*[[Sildenafil]]
*[[Sildenafil]]
*Complications include hypotension with administration of nitrates, flushing, epistaxis, headache
*Complications include hypotension with administration of nitrates, flushing, epistaxis, headache
===Endothelin receptor antagonists===
===Endothelin receptor antagonists===
'''Mechanism of Action''': vasodilation via vascular modulation
Mechanism of Action: vasodilation via vascular modulation
*[[Bosentan]], Ambrisentan
*[[Bosentan]], Ambrisentan
**Complications include liver failure, supratherapeutic INR,  
**Complications include liver failure, supratherapeutic INR,  

Latest revision as of 09:24, 22 March 2026

This page is for adult patients. For pediatric patients, see: pulmonary hypertension (peds)

Background

Pulmonary circuit anatomy.
Micrograph showing arteries in pulmonary hypertensive with marked thickening of the walls.
Three major signaling pathways involved in the pathogenesis of pulmonary arterial hypertension.
  • Mean PA pressure >25 mmHg as assessed by right heart catheterization
    • Since right ventricle is dependent on preload, RV contractility and afterload, severe pulmonary arterial hypertension causes pathological changes to right ventricle

WHO Classification[1]

Etiologies

Clinical Features

History

Physical exam

Differential Diagnosis

Acute dyspnea

Emergent

Non-Emergent

Evaluation

CT chest with contrast showing prulmonary artery hypertension (red arrow) and evidence of emphysema (blue arrow).

Some, all or none of the following findings may be present.

  • BNP: Elevated[2]
  • ECG findings (similar to acute pulmonary embolism):
    • Right axis deviation
    • Evidence of right heart strain on bedside ultrasound or CT
    • S1Q3T3 ECG finding
    • Twave inversions on ECG in inferior and anteroseptal leads
    • Right ventricular hypertrophy
  • Large R waves in precordial leads
  • Tachyarrhythmias (atrial flutter or atrial fibrillation if new portend poorer prognosis)[3]

CXR Abnormalities

    • RA enlargement (obliteration of retrosternal space on lateral CXR)
    • Prominent pulmonary vasculature (congestion)
    • PA dilation

CTA Chest Abnormalities

  • Pulmonary artery > ascending aorta suggests PH
  • Pulmonary artery diameter greater than 30 mm suggest PH
  • Right heart enlargement

Echocardiographic Findings

  • D sign (McConnel's Sign)
  • RV close to LV size (+/- septal flattening/bowing)
  • Tricuspid valve regurgitation
  • Estimate systolic pulmonary artery pressure (SPAP) with echo[4]
    • SPAP = Max TR gradient + Mean RAP
    • Cannot use this method with vent-dependent patients, pulmonic stenosis
    • Max TR gradient as measured by tricuspid regurgitation (TR) jet, which >90% of adults have
    • Use parallel CW Doppler line across TR jet in apical view
    • Obtain dense TR profile below the line with well-defined envelope and measure peak = Max TR gradient
    • Estimate right atrial pressure (RAP) with IVC diameter from subcostal view
Normal Intermediate High
Mean RAP, mmHg 3 8 15
IVC diameter max 2.1 max 2.1 > 2.1
Resp variation >50% <50% <50%

Evaluation

  • Initial diagnosis not typically made in the ED because right-sided heart catheterization needed for definitive diagnosis[2]

Acute Management

General Principles of Management for Hypotensive Patient with Pulmonary Hypertension

Consult specialist early. These patients are critically-ill with altered physiology and have very high mortality


First intervention should always be to check any medication pumps. Resume medication immediately. If malfunctioning or empty, most pumps/patients have card with hot-line to call if their pulmonologist is not available

  1. Assess for triggers for decompensation (Treat infection. Consider pulmonary embolism. Evaluate for arrhythmia)
  2. Assess volume status. IVC ultrasound less helpful as will be dilated at baseline. Generally want to avoid fluids. PH patients do not tolerate rapid changes in hemodynamics.
  3. Consider early inotropes and pressors
  4. For tachydysarrhythmia, avoid AV nodal blocking agents like beta blockers or calcium channel blockers. Decrease in inotropy can be fatal. Do NOT rate control. Consider cardioversion and rhythm control
  5. Avoid intubation/NIPPV if at all possible. Positive pressure ventilation can diminish preload which can lead to rapid decompensation and death
  6. Further details below

Optimize Circulation

  1. Optimize (usually reduce) RV preload:
    • Usually euvolemic or hypervolemic, rarely need IV fluids so diuretics can benefit and treat the RV failure[5]
      • Furosemide 20-40mg IV
      • Furosemide drip at 5-20mg/hr
    • If suspect sepsis or hypovolemia, small (250-500cc) NS challenge to assess fluid responsiveness. If not responsive to IVF challenge, start vasopressin or norepinephrine(MAP > 65 mmHg).
  2. Increase cardiac output:
    • Once MAP >65 mmHg, start low dose dobutamine (5-10mcg/kg/min)
    • Improves inotropic support and theoretically decreases pulmonary vascular resistance
  3. Reduce RV afterload:
    • Avoid hypoxia, maintain O2 sat >90% (increases pulmonary vasoconstriction)
    • Avoid hypercapnia (increases pulmonary vascular resistance)
    • Avoid acidosis
  4. Treat arrhythmias:
    • SVT most common although may also become bradycardic (aflutter and afib occur equally)
    • Treatment of aflutter is often more successful than afib
    • Do not tolerate negative inotropy, deteriorate to RV failure
  • May require radiofrequency ablation
  • AVOID calcium channel blockers or β-blockers

Optimize Oxygenation

  • noninvasive oxygenation: attempt nonrebreather mask or high flow nasal cannula to maximize oxygenation. Use NIPPV with caution as positive pressure decreases preload and increases right sided pressures.
  • Intubate as a last resort: RSI meds cause hypotension worsening RV ischemia. hypercapnea and hypoxia worsen pulmonary artery vasoconstriction. positive pressure ventilation decreases preload and increases right sided pressures.
  • Intubated patients should be optimized to increased O2 delivery and minimize hypercapnia, maintain low tidal volumes and low PEEP as tolerated

Early Consultation[2]

  • May require interventions not readily available in the ED:
    • Pulmonary arterial catheter
    • Inhaled pulmonary vasodilators
    • Mechanical support with right ventricular assist device or ECMO

Chronic Therapies

Prostacyclins

Mechanisms of action: vasodilatation, inhibit platelet aggregation

  • Epoprostenol, Iloprost, Treprostinil, Beraprost
    • Complications include acute decompensation if stopped abruptly, diarrhea, edema, headache

Phosphodiesterase Type 5 (PDE5) Inhibitors

Mechanism of Action: vasodilation, increases RV contractility

  • Sildenafil
  • Complications include hypotension with administration of nitrates, flushing, epistaxis, headache

Endothelin receptor antagonists

Mechanism of Action: vasodilation via vascular modulation

  • Bosentan, Ambrisentan
    • Complications include liver failure, supratherapeutic INR,
  • Patients also usually taking digoxin, warfarin, diuretics, home O2. RARELY are they on CCBs only if responsive during cath. Consider line infections as complication to chronic infusions.

Disposition

  • Low threshold for admission if acute decompensation

See Also

References

  1. ↑ Ryan, J. et al. (2012) The WHO classification of pulmonary hypertension: A case-based imaging compendium. Pulmonary Circulation, 2(1).
  2. ↑ 2.0 2.1 2.2 2.3 Wilcox et al. "Pulmonary Hypertension and Right Ventricular Failure in Emergency Medicine." Annals of EM. Dec 2015. 66(6):619-631
  3. ↑ Geibel A et al. Prognostic value of the ECG on admission in patients with acute major pulmonary embolism. European Respiratory Journal. 2005. 25: 843-848
  4. ↑ Critical USG. Echocardiographic assessment of pulmonary artery pressure. 2012. http://www.criticalusg.pl/en/echo/tte/tutorials/echocardiographic-assessment-of-pulmonary-artery-pressures
  5. ↑ Ternacle, J et al. Diruetics in Normotensive Patients with Acute Pulmonary Embolism and Right Ventricular Dilation. Circulation Journal. Vol 77(10) 2013. 2612-618.
Retrieved from "https://www.wikem.org/w/index.php?title=Pulmonary_hypertension&oldid=389053"